Phospholipase C gene expression, protein content, and activities in cardiac hypertrophy and heart failure due to

Melissa R Dent1, Naranjan S Dhalla, Paramjit S Tappia

  • 1Department of Physiology, Faculty of Medicine, St Boniface General Hospital Research Centre University of Manitoba, Winnipeg, Manitoba R2H 2A6, Canada.

Insights

Volume overload from arteriovenous shunts causes cardiac hypertrophy and heart failure. Phosphoinositide phospholipase C (PLC) isozyme activity changes, impacting cardiac function during these conditions.

Area of Science:

  • Cardiovascular Physiology
  • Molecular Cardiology
  • Biochemistry

Background:

  • Volume overload from arteriovenous (AV) shunts induces cardiac hypertrophy and can progress to heart failure.
  • Phosphoinositide phospholipase C (PLC) enzymes play a role in cardiac function by metabolizing phosphatidylinositol 4,5-bisphosphate (PIP(2)).

Purpose of the Study:

  • To investigate the dynamic changes in diacylglycerol (DAG) and inositol (1,4,5)-trisphosphate (IP(3)) levels.
  • To analyze the time-course of alterations in phosphoinositide phospholipase C (PLC) isozyme gene expression, protein content, and enzymatic activity.
  • To correlate these molecular changes with cardiac hypertrophy and heart failure induced by AV shunt in a rat model.

Main Methods:

  • Induction of volume overload using an AV shunt in Sprague-Dawley rats.
  • Measurement of left ventricle (LV)-to-body weight ratio to confirm cardiac hypertrophy.
  • Quantification of PLC isozyme (beta(1), gamma(1), delta(1)) mRNA, protein levels, and enzymatic activities at various time points.
  • Assessment of sarcolemmal (SL) PIP(2) content.

Main Results:

  • Cardiac hypertrophy was confirmed by increased LV-to-body weight ratio at 4 weeks.
  • PLC-beta(1) activity, mRNA, and protein increased early (3 days to 2 weeks) but normalized by 4 weeks, then increased again at later time points (8-16 weeks).
  • PLC-gamma(1) activity, mRNA, and protein increased at 3 days and 4 weeks, while PLC-delta(1) activity, gene expression, and protein decreased progressively from 1 to 4 weeks, with further depression at 8-16 weeks.
  • Sarcolemmal PIP(2) content progressively decreased during hypertrophy and heart failure.

Conclusions:

  • Phosphoinositide phospholipase C (PLC) isozyme signaling is upregulated during the development of cardiac hypertrophy.
  • PLC isozyme signaling is altered, with decreased activity of certain isoforms, in the progression to heart failure due to volume overload.
  • These findings highlight the complex role of PLC isozymes in the pathophysiology of pressure overload-induced cardiac remodeling and dysfunction.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...